oral, allosteric PRC2 inhibitor (EED) - Novartis, Emeryville, CA

oral, allosteric PRC2 inhibitor (EED)

in Ph. I/II for cancer (DLBCL); preliminary efficacy

from micromolar HTS hit

J. Med. Chem.

Novartis, Emeryville, CA

Context. MAK683 is an oral, allosteric and selective PRC2 inhibitor intended for PRC2-dependent cancers. PRC2 is an essential epigenetic regulator of gene expression and enhanced or diminished PRC2 function…


 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.